Absolute Quantification.
Seamless Proteomics.
NEWS:
Collaboration between ProteomEdge and the Proteomics Core Facility at the University of Gothenburg
We’re happy to announce that the Proteomics Core Facility (PCF) at the University of Gothenburg now extends their service by offering comprehensive research support for mass spectrometry based absolute protein quantification using the ProteomEdge panels.
As part of the BioMS (the Swedish National Infrastructure for Biological Mass Spectrometry) and SciLifeLab (a Swedish national research infrastructure), PCF has extensive experience in proteome studies within medicine and life science. The facility is equipped with state‑of‑the‑art high‑resolution mass spectrometers and provides advanced expertise to the research community.
By integrating ProteomEdge’s qRePS™-based panels into their service offering, PCF enables researchers to access robust, multiplexed absolute protein quantification with high precision and scalability.
“This collaboration lowers the barrier to high-quality absolute quantification in plasma proteomics and beyond. By combining ProteomEdge’s assays with PCF’s research support we will make robust, quantitative proteomics accessible to the wider research community,” said Henrik Everberg, CEO of ProteomEdge.
“PCF is excited about this new opportunity for the life science and precision medicine community,” said Carina Sihlbom Wallem, Head of the Proteomics Core Facility.
Researchers interested in accessing the service are encouraged to contact PCF directly for further information.
2025 HIGHLIGHTS
ProteomEdge Secures 7.8 million SEK in Funding to Accelerate Commercialization and Appoints New CEO
ProteomEdge is proud to announce the successful closure of a 7.8 million SEK funding round, led by Navigare Ventures, a subsidiary of Wallenberg Investments AB, with strong participation from existing shareholders.
This investment fuels our mission to deliver a cutting-edge analytical platform for absolute protein quantification using mass spectrometry. Our growing portfolio of proprietary products, targeting a large set of clinically relevant plasma biomarkers such as apolipoproteins, complement factors, and liver biomarkers, is already making impact in key research areas.
“This investment will enable us to expand our proprietary product line of internal standards for mass spectrometry platforms and bring them to market faster,” said Professor Mathias Uhlén, Co-founder and Chairman of the Board.
“Navigare Ventures is excited to lead this funding round to support the ProteomEdge team and their vision to bring precision into absolute proteome quantification for next-generation blood profiling,” said Elin Almstedt, Principal at Navigare Ventures.
We are also pleased to welcome Dr. Henrik Everberg as our new full-time Chief Executive Officer, starting August 2025. Dr. Everberg brings two decades of experience in the life science sector, with leadership roles at companies including PhaDia, Atlas Antibodies, and most recently as COO of Pixelgen Technologies. He succeeds Dr. Marianne Hansson, who has served as part-time CEO during our formative phase—our sincere thanks for her impactful leadership.
Stay tuned as ProteomEdge continues to push the boundaries of applied mass spectrometry-based proteomics and transform the future of blood-based precision medicine.
Our Story
ProteomEdge™ is a company from Stockholm, Sweden, started by researchers at the Human Protein Atlas program (www.proteinatlas.org) and the national infrastructure Science for Life Laboratory (www.scilifelab.se).
The company is developing proprietary analysis platforms based on mass spectrometry to offer labeled protein standards for a wide range of protein targets of both clinical and research interest.
Our first product, ApoEdge™, was released November 1, 2023 and is a panel including all 18 different apolipoproteins for analyses of blood plasma. In April 2024 we released our DiscoveryEdge™175, a panel covering 176 interesting human protein targets, including complement factors, inflammatory markers, cancer markers and more. In June 2024, we introduced our ComplemEdge panel including 81 different proteins involved in the complement cascade and in August our LiverEdge panel with 39 liver disease related proteins was released.
One more targeted panel and a lager Discovery panel are in the pipeline, estimated to be released in the beginning of 2026.
Vision
Bringing precision into absolute proteome quantification for next generation blood profiling.
Mission
Providing an analytical platform for state-of-the-art accuracy for absolute protein quantification using mass spectrometry.